FDA Expands Tzield for Children; But Keeps Deadly Infection Warning

The U.S. Food and Drug Administration has expanded the indication of Tzield, developed by Sanofi SA, to include children and adolescents aged 8 to 17 who have recently been diagnosed with stage 3 type 1 diabetes. This update broadens the